Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550

Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy

Riaz, F., Huang, Z., & Pan, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1280741 · Cited by 20

Cancer Immunotherapy and the Nectin Family

Johnston, R. J., Lee, P. S., Strop, P., & Smyth, M. J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060920-084910 · Cited by 19

Effect of pembrolizumab on CD4+CD25+, CD4+LAP+ and CD4+TIM-3+ T cell subsets

Toor, S. M., Nair, V. S., Pfister, G., & Elkord, E. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13264 · Cited by 20

Evaluating the impacts of emerging cancer therapies on ovarian function

Alesi, L. R., Winship, A., & Hutt, K. J. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.12.004 · Cited by 19

The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications

Piseddu, I., Mayerle, J. V., Mahajan, U. M., & Boehmer, D. F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335375 · Cited by 22

Considering B7-CD28 as a family through sequence and structure

West, S. M., & Deng, X. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219855970 · Cited by 19

Proteomics as a Complementary Technique to Characterize Bladder Cancer

López-Cortés, R., Vázquez‐Estévez, S., Fernández, J. Á., & Núñez, C. (2021) · Cancers · doi:10.3390/cancers13215537 · Cited by 18

Immunotherapy Toxicities

Sanchez, K. G., Page, D. B., & Urba, W. J. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.009 · Cited by 18

ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control

Blair, T. C., Baird, J. R., Bambina, S., Kramer, G. F., Gostissa, M., Harvey, C. J., Gough, M. J., & Crittenden, M. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-19256-8 · Cited by 20

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

Mukherjee, D., Romano, E., Walshaw, R. C., Zeef, L. A. H., Banyard, A., Kitcatt, S. J., Cheadle, E. J., Tuomela, K., Pendharkar, S., Al-Deka, A., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2223094 · Cited by 17

CD36 — the Achilles’ heel of Treg cells

Horton, B. L., & Spranger, S. (2020) · Nature Immunology · doi:10.1038/s41590-020-0601-0 · Cited by 17

Advances in the discovery and development of melanoma drug therapies

Chanda, M., & Cohen, M. S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1942834 · Cited by 21

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy

Kong, B. Y., Bolton, H. A., Kim, J. W., Silveira, P. A., Fromm, P. D., & Clark, G. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00050 · Cited by 19

CTLA-4—two pathways to anti-tumour immunity?

Ward, F. J., Kennedy, P. T., Al-Fatyan, F., Dahal, L. N., & Eid, R. A. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf008 · Cited by 16

Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

Jiang, X., Rudqvist, N.-P., Jiang, B., Ye, S., He, S., Liang, Q., Dou, J., Williams, M. D., Dunn, J. D., Johnson, J. M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1390 · Cited by 17

The Role of Antibody-Based Therapies in Neuro-Oncology

Ramapriyan, R., Sun, J., Curry, A., Richardson, L. G., Ramesh, T., Gaffey, M., Gedeon, P. C., Gerstner, E. R., Curry, W. T., & Choi, B. D. (2023) · Antibodies · doi:10.3390/antib12040074 · Cited by 19

The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

Attias, M., & Piccirillo, C. A. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16313 · Cited by 17

Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis

Nahar, K. J., Marsh‐Wakefield, F., Rawson, R. V., Gide, T. N., Ferguson, A. L., Allen, R. O., Quek, C. Y. J., da Silva, I. P., Tattersall, S., Kiely, C. J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157839 · Cited by 16

Regulatory T cells as therapeutic targets and mediators

Sharma, A., & Rudra, D. (2019) · International Reviews of Immunology · doi:10.1080/08830185.2019.1621310 · Cited by 17

Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment

Fang, T., Xiao, J., Zhang, Y., Hu, H., Zhu, Y., & Cheng, Y. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-20-173 · Cited by 15

Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives

Liu, J., He, C., Tan, W., & Zheng, J. H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122897 · Cited by 14

Cancer evolution: Special focus on the immune aspect of cancer

Hu, X., Chen, Z., Wang, Z., & Xiao, Q. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.006 · Cited by 14

Turning up the heat: CTLA4 blockade in urothelial cancer

Stockem, C. F., Galsky, M. D., & van der Heijden, M. S. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00801-7 · Cited by 15

Aptamer-mediated transcriptional gene silencing of Foxp3 inhibits regulatory T cells and potentiates antitumor response

Manrique-Rincón, A., Ruas, L. P., Fogagnolo, C. T., Brenneman, R., Berezhnoy, A., Castelucci, B. G., Consonni, S. R., Gilboa, E., & Bajgelman, M. C. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.005 · Cited by 14

Neurological Immunotoxicity from Cancer Treatment

Wesley, S. F., Haggiagi, A. M., Thakur, K. T., & Jager, P. L. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136716 · Cited by 15

ACSL4 Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer

Luo, W., Wang, J., Dai, X., Zhang, H., Qu, Y., Xiao, W., Ye, D., & Zhu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754845 · Cited by 14

HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab

Ladányi, A., Hegyi, B., Balatoni, T., Liszkay, G., Rohregger, R., Waldnig, C., Dudás, J., & Ferrone, S. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610297 · Cited by 14

FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer

Grell, P., Bořilová, S., Fabián, P., Selingerová, I., Novak, D., Müller, P., Kišš, I., & Vyzula, R. (2023) · Cancers · doi:10.3390/cancers15061901 · Cited by 18

Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization

Edmunds, G. L., Wong, C. C. W., Ambler, R., Milodowski, E., Alamir, H., Cross, S., Galea, G., Wülfing, C., & Morgan, D. J. (2022) · Communications Biology · doi:10.1038/s42003-021-02972-8 · Cited by 14

Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice

Du, W.-Y., Masuda, H., Nagaoka, K., Yasuda, T., Kuge, K., Seto, Y., Kakimi, K., & Nomura, S. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01514-5 · Cited by 13

Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment

Guisier, F., Barros‐Filho, M. C., Rock, L. D., Strachan-Whaley, M. R., Marshall, E. A., Dellaire, G., & Lam, W. L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35723-8_3 · Cited by 16

Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic

Ljubimov, V. A., Ramesh, A., Davani, S., Danielpour, M., Breunig, J. J., & Black, K. L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114033 · Cited by 13

Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser

Omland, S. H., Ejlertsen, J. S., Krustrup, D., Christensen, R. L., Svane, I. M., Olesen, U. H., & Hædersdal, M. (2022) · Cancers · doi:10.3390/cancers14235815 · Cited by 12

Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy

Műzes, G., & Sípos, F. (2023) · Biomedicines · doi:10.3390/biomedicines11041130 · Cited by 13

The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?

Giacomo, A. M. D., Lahn, M., Eggermont, A. M. M., Fox, B. A., Ibrahim, R. A., Sharma, P., Allison, J. P., & Maio, M. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113501 · Cited by 13

Identification of Treg-related prognostic molecular subtypes and individualized characteristics in clear cell renal cell carcinoma through single-cell transcriptomes and bulk RNA sequencing

Weng, K. Q., Liu, J. Y., Hu, L., She, L. L., Qiu, J., Qi, H., Qi, H. Y., Li, Y.-S., & Dai, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111746 · Cited by 12

Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells

Gampa, G., Spinosa, P. C., Getz, J. A., Zhong, Y. M., Halpern, W., Esen, E., Davies, J., Chou, C. K., Kwong, M., Wang, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16326 · Cited by 13

Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade

Blanchard, L., Vina, E., Ljubetic, J., Meneur, C., Tarroux, D., Baez, M., Marino, A. E., Ortéga, N., Knorr, D. A., Ravetch, J. V., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102141 · Cited by 14

OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma

Lu, Y., Li, Y., Yu, J., Meng, S., Bi, C., Guan, Q., Li, L., Qiu, L., Qian, Z., Zhou, S., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109637 · Cited by 12

Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Bugno, J., Wang, L., Yu, X., Cao, X., Wang, J., Huang, X., Yang, K., Piffkó, A., Chen, K. S., Luo, S. Y., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3616 · Cited by 12

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

da Silva, I. P., Li, I., Ugurel, S., Serra-Bellver, P., Andhale, A., Burnette, H., Aya, F., Conway, J. W., Braden, J., Carlino, M. S., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114101 · Cited by 12

Modeling the effect of immunotherapies on human castration-resistant prostate cancer

Coletti, R., Pugliese, A., & Marchetti, L. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110500 · Cited by 11

VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis

Conway, J. W., Braden, J., Lo, S., Scolyer, R. A., Carlino, M. S., Menzies, A. M., Long, G. V., & da Silva, I. P. (2023) · Cancers · doi:10.3390/cancers15205012 · Cited by 11

Knowledge-map analysis of bladder cancer immunotherapy

Lv, Z., Hou, J., Wang, Y., Wang, X., Wang, Y., & Wang, K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2267301 · Cited by 11

Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition

Singh, R. K., Srivastava, P., & Manna, P. P. (2024) · Medical Oncology · doi:10.1007/s12032-023-02289-y · Cited by 11

Archetypes of checkpoint-responsive immunity

Im, K. W., Combes, A. J., Spitzer, M. H., Satpathy, A. T., & Krummel, M. F. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.007 · Cited by 13

Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody

Belli, S., Amann, M., Hutchinson, L. G., Pousse, L., Abdolzade‐Bavil, A., Justies, N., Jacobsen, B., Ploix, C. C., Tselempi, E., Toševski, V., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3303 · Cited by 9

Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

Willoughby, J. E., Dou, L., Bhattacharya, S., Jackson, H. L., Seestaller‐Wehr, L., Kilian, D., Bover, L. C., Voo, K. S., Cox, K. L., Murray, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008677 · Cited by 10

Elucidating CTLA-4’s role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments

Fu, J., Mao, L., Yu, J., Mei, D., & Chen, Y. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10917-6 · Cited by 10

The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma

Scognamiglio, G., Capone, M., Sabbatino, F., Mauro, A. D., Cantile, M., Cerrone, M., Madonna, G., Grimaldi, A. M., Mallardo, D., Palla, M., et al. (2021) · Cancers · doi:10.3390/cancers13102325 · Cited by 10

Correlation between aryl hydrocarbon receptor and IL‐17+ and Foxp3+ T‐cell infiltration in bladder cancer

Fattahi, S., Karimi, M., Ghatrehsamani, M., Taheri, F., Shirzad, H., Beigi, F. M. A., Anjomshoa, M., & Bagheri, N. (2021) · International Journal of Experimental Pathology · doi:10.1111/iep.12392 · Cited by 10

A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators

Pu, D., Liu, D., Li, C., Chen, C., Che, Y., Lv, J., Yang, Y., & Wang, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.933798 · Cited by 9

Induction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137

Sun, R., Lee, K. Y., Mei, Y., Nickles, E. P., Lin, J. L., Xia, R., Liu, H., & Schwarz, H. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2443265 · Cited by 10

Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population

Wolf, S., Madanchi, M., Turko, P., Hollmén, M., Tugues, S., von Atzigen, J., Giovanoli, P., Dummer, R., Lindenblatt, N., Halin, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55002-6 · Cited by 10

Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification

Peng, Z., Wang, J., Tong, S., Wu, Y., Yi, D., & Xiang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128151 · Cited by 9

Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA

Xue, Y., Zhao, G., Pu, X., & Jiao, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196802 · Cited by 9

Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor‐induced immune‐related adverse events

Cina, M. L., Venegas, J., & Young, A. (2023) · Immunological Reviews · doi:10.1111/imr.13250 · Cited by 10

A new approach to overcoming resistance to immunotherapy: nanotechnology

Shao, J., Jin, Y. H., & Jin, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210245 · Cited by 10

Finding the Right Heavy Chains for Immunostimulatory Antibodies

Boulard, P., Gouilleux‐Gruart, V., & Watier, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810367 · Cited by 9

Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy

Kolb, H. R., Borcherding, N. C., & Zhang, W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_12 · Cited by 9

Targeting T regulatory (T reg ) cells in immunotherapy-resistant cancers

Spiliopoulou, P., Kaur, P., Hammett, T., Conza, G. D., & Lahn, M. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.46 · Cited by 8

Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting

Zervanos, D.-I., Galatou, E., Miliotou, Α. N., Theodoroula, N. F., Grigoriadis, N., & Vizirianakis, I. S. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030043 · Cited by 8

Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development

Navarrete, M., Costoya, C., Gálvez‐Cancino, F., Peggs, K. S., Marabelle, A., & Quezada, S. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-123559 · Cited by 8

Regulatory T cells in cancer and inflammation

Yang, H., Zhang, H., Xia, N., & Cheng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02584-w · Cited by 8

Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation

Walkovich, K. J., & Connelly, J. A. (2021) · Hematology · doi:10.1182/hematology.2021000285 · Cited by 9

Ipilimumab Combination Dosing: Less is More

Jameson-Lee, M., & Luke, J. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2406 · Cited by 8

Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines

Nakazawa, M., Charmsaz, S., Hallab, E., Fang, M., Kao, C., Brancati, M., Munjal, K., Li, H. L., Leatherman, J. M., Griffin, E., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1055 · Cited by 7

Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?

Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L., & Spiliopoulou, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094393 · Cited by 9

Hybrid regulatory T cells: camouflaged architects of tumor immunity

Azimnasab-sorkhabi, P., Soltani-asl, M., Kfoury, J. R., & Ansa-Addo, E. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658576 · Cited by 7

The effects of local irradiation on circulating lymphocytes in dogs receiving fractionated radiotherapy

Kent, M. S., Emami, S., Rebhun, R. B., Théon, A. P., Hansen, K. S., & Sparger, E. E. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12531 · Cited by 7

Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology

Garg, T., Weiss, C. R., & Sheth, R. A. (2022) · Cancers · doi:10.3390/cancers14153628 · Cited by 7

Repurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity

Sukhatme, V. V., Ramalingam, S. S., Ahmed, R., & Sukhatme, V. P. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000368 · Cited by 7

Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors

Ohm, B., & Jungraithmayr, W. (2022) · Cancers · doi:10.3390/cancers15010289 · Cited by 7

Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacyPreprint

Stone, E. L., Carter, K. P., Wagner, E. K., Asensio, M. A., Benzie, E., Chiang, Y., Coles, G. L., Edgar, C., Gautam, B. K., Gras, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.12.452090 · Cited by 7

Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancerPreprint

Ager, C. R., Obradović, A., McCann, P. J., Chaimowitz, M. G., Wang, A. L. E., Shaikh, N., Shah, P., Pan, S. M., Laplaca, C. J., Virk, R. K., et al. (2024) · medRxiv · doi:10.1101/2024.09.09.24313308 · Cited by 7

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerPreprint

Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.640711 · Cited by 7

Quantitative Systems Pharmacology Modeling in Immuno-Oncology: Hypothesis Testing, Dose Optimization, and Efficacy Prediction

Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · Handbook of Experimental Pharmacology · doi:10.1007/164_2024_735 · Cited by 6

From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer

Burns, C. P., Parker, J. M., Schaap, D. M., Wakefield, M. R., & Fang, Y. (2025) · Cancers · doi:10.3390/cancers17071135 · Cited by 6

Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors

Lu, H., Teng, Z., Wang, J., & Zhang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583363 · Cited by 7

Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study

Lü, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. M. (2024) · BMC Cancer · doi:10.1186/s12885-024-12196-8 · Cited by 6

Challenges and advances of immune checkpoint therapy

Li, L., & Sun, Y. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.70001 · Cited by 7

The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis

Qiu, Q., Deng, C., Li, H., Qiu, J., Shen, Z., & Ding, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.999203 · Cited by 6

CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events.

Tian, C., Wang, X.-H., & Zhang, S. (2023) · PubMed Central · Cited by 5

Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study

Zhang, P., Chen, K., Yang, J., Song, L., Zheng, F., Luo, R., He, Y., Li, F., Yang, D., Cao, N., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103249 · Cited by 5

CD25+FOXP3+CD45RA− regulatory T-cell infiltration as a prognostic biomarker for endometrial carcinoma

Suto, A., Minaguchi, T., Qi, N., Fujieda, K., Itagaki, H., Tenjimbayashi, Y., Shikama, A., Tasaka, N., Akiyama, A., Nakao, S., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12851-0 · Cited by 5

Induced Vascular Normalization—Can One Force Tumors to Surrender to a Better Microenvironment?

Sun, X., Nosrati, Z., Ko, J., Lee, C.-M., Bennewith, K. L., & Bally, M. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082022 · Cited by 8

Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy

Lucas, S. N., & Thomas, S. N. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00692 · Cited by 5

Antipodoplanin antibody enhances the antitumor effects of CTLA ‐4 blockade against malignant mesothelioma by natural killer cells

Yoneda, H., Mitsuhashi, A., Yoshida, A., Ogino, H., Itakura, S., Nguyen, N. T., Nokihara, H., Sato, S., Shinohara, T., Hanibuchi, M., et al. (2023) · Cancer Science · doi:10.1111/cas.16046 · Cited by 5

Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets

Bujanda, Z. A. L., Hadavi, S. H., de Porras, V. R., Martinez‐Balibrea, E., & Dallos, M. C. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.008 · Cited by 5

Mechanism of Action and Pharmacologic Features of Drugs Targeting PD ‐1/ PDL ‐1 and CTLA ‐4

Rodriguez, M., Bucktrout, R., Orlando, A., Serganova, I. S., & Zappasodi, R. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch11 · Cited by 5

Progress of immune checkpoint inhibitors in gastric cancer

Wan, J.-Y., Zhang, D., Wu, X., Yang, H., & Dong, C. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i8.109613 · Cited by 4

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial

Ager, C. R., Obradović, A., McCann, P., Chaimowitz, M. G., Wang, A. L. E., Shaikh, N., Shah, P., Pan, S. S., Laplaca, C. J., Virk, R. K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102638 · Cited by 11

Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls

Mirallas, O., Pretelli, G., Pena, M. B., Jiménez-Labaig, P., Hernando-Calvo, A., Tan, H. N., Selvadurai, P. N., de Lara, P. T., Vieito, M., Martín-Liberal, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.015 · Cited by 5

Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Zhang, N., Liu, T., Luo, M., Hao, J., Qin, S., Zhang, Y., Wang, G., Chen, Y., Zhang, J., Gu, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3412 · Cited by 4

Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma

Marks, K. E., Horisberger, A., Elahee, M., Adejoorin, I., Ghosh, N., Postow, M. A., Donlin, L. T., Bass, A. R., & Rao, D. A. (2025) · JCI Insight · doi:10.1172/jci.insight.198203 · Cited by 4

Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors

Zhang, C., Chien, C., Jurgaitytė, E., Sakiyama, K., Bockman, A., Jo, Y., Lee, S., Silveria, S. L., Andrews, E., Mende, A., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adx4411 · Cited by 4

Effect of Cytotoxic T-Lymphocyte Antigen-4 on the Efficacy of the Fatty Acid-Binding Protein Vaccine Against Schistosoma japonicum

Tang, C., Pan, Q., Xie, Y., Xiong, Y., Zhang, R., & Huang, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01022 · Cited by 4

CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade

Smithy, J. W., & Luke, J. J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0490 · Cited by 4

Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy

Knight, A. D., & Luke, J. J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01551-4 · Cited by 4

Immune-checkpoint inhibitor resistance in patients with cancer

Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003196 · Cited by 4

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response

Sharma, A., Subudhi, S. K., Blando, J. M., Vence, L. M., Wargo, J. A., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 317

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Letter

Ferrara, R., Susini, S., & Marabelle, A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3740 · Cited by 29

Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

Ribas, A., Comı́n-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 132

Regulatory T cells in cancer immunotherapy

Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 721

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472